Trial watch: chemotherapy-induced immunogenic cell death in oncology
ABSTRACTImmunogenic cell death (ICD) refers to an immunologically distinct process of regulated cell death that activates, rather than suppresses, innate and adaptive immune responses. Such responses culminate into T cell-driven immunity against antigens derived from dying cancer cells. The potency...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2219591 |
| _version_ | 1797367123943620608 |
|---|---|
| author | Jenny Sprooten Raquel S. Laureano Isaure Vanmeerbeek Jannes Govaerts Stefan Naulaerts Daniel M. Borras Lisa Kinget Jitka Fucíková Radek Špíšek Lenka Palová Jelínková Oliver Kepp Guido Kroemer Dmitri V. Krysko An Coosemans Rianne D.W. Vaes Dirk De Ruysscher Steven De Vleeschouwer Els Wauters Evelien Smits Sabine Tejpar Benoit Beuselinck Sigrid Hatse Hans Wildiers Paul M. Clement Peter Vandenabeele Laurence Zitvogel Abhishek D. Garg |
| author_facet | Jenny Sprooten Raquel S. Laureano Isaure Vanmeerbeek Jannes Govaerts Stefan Naulaerts Daniel M. Borras Lisa Kinget Jitka Fucíková Radek Špíšek Lenka Palová Jelínková Oliver Kepp Guido Kroemer Dmitri V. Krysko An Coosemans Rianne D.W. Vaes Dirk De Ruysscher Steven De Vleeschouwer Els Wauters Evelien Smits Sabine Tejpar Benoit Beuselinck Sigrid Hatse Hans Wildiers Paul M. Clement Peter Vandenabeele Laurence Zitvogel Abhishek D. Garg |
| author_sort | Jenny Sprooten |
| collection | DOAJ |
| description | ABSTRACTImmunogenic cell death (ICD) refers to an immunologically distinct process of regulated cell death that activates, rather than suppresses, innate and adaptive immune responses. Such responses culminate into T cell-driven immunity against antigens derived from dying cancer cells. The potency of ICD is dependent on the immunogenicity of dying cells as defined by the antigenicity of these cells and their ability to expose immunostimulatory molecules like damage-associated molecular patterns (DAMPs) and cytokines like type I interferons (IFNs). Moreover, it is crucial that the host’s immune system can adequately detect the antigenicity and adjuvanticity of these dying cells. Over the years, several well-known chemotherapies have been validated as potent ICD inducers, including (but not limited to) anthracyclines, paclitaxels, and oxaliplatin. Such ICD-inducing chemotherapeutic drugs can serve as important combinatorial partners for anti-cancer immunotherapies against highly immuno-resistant tumors. In this Trial Watch, we describe current trends in the preclinical and clinical integration of ICD-inducing chemotherapy in the existing immuno-oncological paradigms. |
| first_indexed | 2024-03-08T17:12:52Z |
| format | Article |
| id | doaj.art-7008e019d7c247f4ac120beabac8edc7 |
| institution | Directory Open Access Journal |
| issn | 2162-402X |
| language | English |
| last_indexed | 2024-03-08T17:12:52Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj.art-7008e019d7c247f4ac120beabac8edc72024-01-03T19:25:36ZengTaylor & Francis GroupOncoImmunology2162-402X2023-12-0112110.1080/2162402X.2023.2219591Trial watch: chemotherapy-induced immunogenic cell death in oncologyJenny Sprooten0Raquel S. Laureano1Isaure Vanmeerbeek2Jannes Govaerts3Stefan Naulaerts4Daniel M. Borras5Lisa Kinget6Jitka Fucíková7Radek Špíšek8Lenka Palová Jelínková9Oliver Kepp10Guido Kroemer11Dmitri V. Krysko12An Coosemans13Rianne D.W. Vaes14Dirk De Ruysscher15Steven De Vleeschouwer16Els Wauters17Evelien Smits18Sabine Tejpar19Benoit Beuselinck20Sigrid Hatse21Hans Wildiers22Paul M. Clement23Peter Vandenabeele24Laurence Zitvogel25Abhishek D. Garg26Cell Stress & Immunity (CSI) Lab, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, BelgiumCell Stress & Immunity (CSI) Lab, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, BelgiumCell Stress & Immunity (CSI) Lab, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, BelgiumCell Stress & Immunity (CSI) Lab, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, BelgiumCell Stress & Immunity (CSI) Lab, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, BelgiumCell Stress & Immunity (CSI) Lab, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, BelgiumLaboratory of Experimental Oncology, Department of Oncology, Leuven Cancer Institute, KU Leuven, Leuven, BelgiumDepartment of Immunology, Charles University, 2ndFaculty of Medicine and University Hospital Motol, Prague, Czech RepublicDepartment of Immunology, Charles University, 2ndFaculty of Medicine and University Hospital Motol, Prague, Czech RepublicDepartment of Immunology, Charles University, 2ndFaculty of Medicine and University Hospital Motol, Prague, Czech RepublicMetabolomics and Cell Biology Platforms, Institut Gustave Roussy Cancer Center, Université Paris Saclay, Villejuif, FranceMetabolomics and Cell Biology Platforms, Institut Gustave Roussy Cancer Center, Université Paris Saclay, Villejuif, FranceCell Death Investigation and Therapy (CDIT) Laboratory, Department of Human Structure and Repair, Ghent University, Ghent, BelgiumLaboratory of Tumor Immunology and Immunotherapy, Department of Oncology, Leuven Cancer Institute, KU Leuven, Leuven, BelgiumDepartment of Radiation Oncology (MAASTRO), GROW School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The NetherlandsDepartment of Radiation Oncology (MAASTRO), GROW School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The NetherlandsDepartment Neurosurgery, University Hospitals Leuven, Leuven, BelgiumLaboratory of Respiratory Diseases and Thoracic Surgery (Breathe), Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, BelgiumCenter for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, BelgiumMolecular Digestive Oncology, Department of Oncology, Katholiek Universiteit Leuven, Leuven, BelgiumLaboratory of Experimental Oncology, Department of Oncology, Leuven Cancer Institute, KU Leuven, Leuven, BelgiumLaboratory of Experimental Oncology, Department of Oncology, Leuven Cancer Institute, KU Leuven, Leuven, BelgiumLaboratory of Experimental Oncology, Department of Oncology, Leuven Cancer Institute, KU Leuven, Leuven, BelgiumLaboratory of Experimental Oncology, Department of Oncology, Leuven Cancer Institute, KU Leuven, Leuven, BelgiumCell Death and Inflammation Unit, VIB-Ugent Center for Inflammation Research (IRC), Ghent, BelgiumTumour Immunology and Immunotherapy of Cancer, European Academy of Tumor Immunology, Gustave Roussy Cancer Center, Inserm, Villejuif, FranceCell Stress & Immunity (CSI) Lab, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, BelgiumABSTRACTImmunogenic cell death (ICD) refers to an immunologically distinct process of regulated cell death that activates, rather than suppresses, innate and adaptive immune responses. Such responses culminate into T cell-driven immunity against antigens derived from dying cancer cells. The potency of ICD is dependent on the immunogenicity of dying cells as defined by the antigenicity of these cells and their ability to expose immunostimulatory molecules like damage-associated molecular patterns (DAMPs) and cytokines like type I interferons (IFNs). Moreover, it is crucial that the host’s immune system can adequately detect the antigenicity and adjuvanticity of these dying cells. Over the years, several well-known chemotherapies have been validated as potent ICD inducers, including (but not limited to) anthracyclines, paclitaxels, and oxaliplatin. Such ICD-inducing chemotherapeutic drugs can serve as important combinatorial partners for anti-cancer immunotherapies against highly immuno-resistant tumors. In this Trial Watch, we describe current trends in the preclinical and clinical integration of ICD-inducing chemotherapy in the existing immuno-oncological paradigms.https://www.tandfonline.com/doi/10.1080/2162402X.2023.2219591CAR T cells, antigen-presenting cellschemotherapydanger signalsdendritic cellimmune-checkpoint blockersimmunogenic cell death |
| spellingShingle | Jenny Sprooten Raquel S. Laureano Isaure Vanmeerbeek Jannes Govaerts Stefan Naulaerts Daniel M. Borras Lisa Kinget Jitka Fucíková Radek Špíšek Lenka Palová Jelínková Oliver Kepp Guido Kroemer Dmitri V. Krysko An Coosemans Rianne D.W. Vaes Dirk De Ruysscher Steven De Vleeschouwer Els Wauters Evelien Smits Sabine Tejpar Benoit Beuselinck Sigrid Hatse Hans Wildiers Paul M. Clement Peter Vandenabeele Laurence Zitvogel Abhishek D. Garg Trial watch: chemotherapy-induced immunogenic cell death in oncology OncoImmunology CAR T cells, antigen-presenting cells chemotherapy danger signals dendritic cell immune-checkpoint blockers immunogenic cell death |
| title | Trial watch: chemotherapy-induced immunogenic cell death in oncology |
| title_full | Trial watch: chemotherapy-induced immunogenic cell death in oncology |
| title_fullStr | Trial watch: chemotherapy-induced immunogenic cell death in oncology |
| title_full_unstemmed | Trial watch: chemotherapy-induced immunogenic cell death in oncology |
| title_short | Trial watch: chemotherapy-induced immunogenic cell death in oncology |
| title_sort | trial watch chemotherapy induced immunogenic cell death in oncology |
| topic | CAR T cells, antigen-presenting cells chemotherapy danger signals dendritic cell immune-checkpoint blockers immunogenic cell death |
| url | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2219591 |
| work_keys_str_mv | AT jennysprooten trialwatchchemotherapyinducedimmunogeniccelldeathinoncology AT raquelslaureano trialwatchchemotherapyinducedimmunogeniccelldeathinoncology AT isaurevanmeerbeek trialwatchchemotherapyinducedimmunogeniccelldeathinoncology AT jannesgovaerts trialwatchchemotherapyinducedimmunogeniccelldeathinoncology AT stefannaulaerts trialwatchchemotherapyinducedimmunogeniccelldeathinoncology AT danielmborras trialwatchchemotherapyinducedimmunogeniccelldeathinoncology AT lisakinget trialwatchchemotherapyinducedimmunogeniccelldeathinoncology AT jitkafucikova trialwatchchemotherapyinducedimmunogeniccelldeathinoncology AT radekspisek trialwatchchemotherapyinducedimmunogeniccelldeathinoncology AT lenkapalovajelinkova trialwatchchemotherapyinducedimmunogeniccelldeathinoncology AT oliverkepp trialwatchchemotherapyinducedimmunogeniccelldeathinoncology AT guidokroemer trialwatchchemotherapyinducedimmunogeniccelldeathinoncology AT dmitrivkrysko trialwatchchemotherapyinducedimmunogeniccelldeathinoncology AT ancoosemans trialwatchchemotherapyinducedimmunogeniccelldeathinoncology AT riannedwvaes trialwatchchemotherapyinducedimmunogeniccelldeathinoncology AT dirkderuysscher trialwatchchemotherapyinducedimmunogeniccelldeathinoncology AT stevendevleeschouwer trialwatchchemotherapyinducedimmunogeniccelldeathinoncology AT elswauters trialwatchchemotherapyinducedimmunogeniccelldeathinoncology AT eveliensmits trialwatchchemotherapyinducedimmunogeniccelldeathinoncology AT sabinetejpar trialwatchchemotherapyinducedimmunogeniccelldeathinoncology AT benoitbeuselinck trialwatchchemotherapyinducedimmunogeniccelldeathinoncology AT sigridhatse trialwatchchemotherapyinducedimmunogeniccelldeathinoncology AT hanswildiers trialwatchchemotherapyinducedimmunogeniccelldeathinoncology AT paulmclement trialwatchchemotherapyinducedimmunogeniccelldeathinoncology AT petervandenabeele trialwatchchemotherapyinducedimmunogeniccelldeathinoncology AT laurencezitvogel trialwatchchemotherapyinducedimmunogeniccelldeathinoncology AT abhishekdgarg trialwatchchemotherapyinducedimmunogeniccelldeathinoncology |